Abstract |
Islet transplantation has proven to be an effective treatment for type 1 diabetes (T1D) yet is hampered by the shortage of available tissue. Recently, two reports from a Viacyte multicenter clinical trial demonstrate the feasibility, safety, and potential efficacy of transplanting macro-encapsulated human stem cell-derived pancreatic endoderm cells into patients with T1D, highlighting the promise of a stem cell-based therapeutic approach.
|
Authors | Holger A Russ, Ali H Shilleh, Lori Sussel |
Journal | Cell metabolism
(Cell Metab)
Vol. 34
Issue 2
Pg. 193-196
(02 01 2022)
ISSN: 1932-7420 [Electronic] United States |
PMID | 35108510
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Comment)
|
Copyright | Copyright © 2022 Elsevier Inc. All rights reserved. |
Topics |
- Cell Differentiation
- Diabetes Mellitus, Type 1
(therapy)
- Endoderm
- Humans
- Islets of Langerhans Transplantation
- Stem Cells
|